Nu Skin Earnings Call Balances Growth and Margin Strain

Nu Skin Enterprises ((NUS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Nu Skin Enterprises’ latest earnings call struck a cautiously optimistic tone, as management highlighted early wins from its new Prysm iO wellness platform, solid subscription and nutrition growth, and a stronger balance sheet, while openly acknowledging profit pressure. Executives stressed that the company is in an investment phase, balancing higher costs and macro headwinds against the foundations being laid for longer-term growth.

Revenue Holds Within Guidance Range

Nu Skin reported first-quarter revenue of $320.6 million, which landed squarely within management’s guidance and included a 1% tailwind from foreign exchange. Leadership reaffirmed full-year guidance, but signaled that investors should expect a more detailed outlook and potentially sharper commentary on trajectory after second-quarter results.

Adjusted Earnings Meet Expectations Despite Charges

Adjusted earnings per share came in at $0.14, aligning with internal expectations once charges tied to winding down the BeautyBio business and other items were excluded. GAAP earnings were a modest $0.04 per share, underscoring how restructuring and strategic investments are weighing on reported profitability in the near term.

Prysm iO Platform Builds Data Scale and Traction

Management highlighted robust early adoption of the Prysm iO device, with nearly 2 million scans conducted from over 30,000 devices and support from 20 million historical biophotonics scans. Subscription volume rose 5% year over year, and subscribers now account for a 14% higher share of total customers, demonstrating growing engagement with the company’s measurement-based wellness ecosystem.

Nutrition Ecosystem and LifePak Drive Growth

Products certified to raise Prysm iO scores are outperforming the broader portfolio, providing tangible proof points for the company’s “test-and-verify” wellness strategy. The flagship LifePak brand delivered more than 10% year-over-year growth, reinforcing management’s push to tie product performance directly to measurable health outcomes.

Regional Momentum in Latin America and China

Nu Skin pointed to sustained growth in Latin America and ongoing improvement in Mainland China, where leaders are rallying around the Tru Face anti-aging rollout. The company is also advancing pre-market efforts in India, positioning for a formal market launch later in the year even though revenue contributions are expected to remain minimal in the near term.

Refinanced Balance Sheet and Capital Return

The company completed a refinancing that extends credit maturities through 2031 and lowers borrowing costs, giving it more financial flexibility as it invests in new initiatives. Nu Skin also returned approximately $8 million to shareholders via $3 million in dividends and $5 million of share repurchases, with $137.3 million still available under its repurchase authorization.

Core Gross Margin Shows Resilience

Core Nu Skin gross margin improved to 76.9%, expanding by 20 basis points versus the prior year and signaling healthy underlying unit economics in the main business. On a consolidated basis, adjusted gross margin held essentially flat at 67.9% compared with 67.8% a year ago, suggesting that top-line pressures are not yet eroding product profitability.

Operating Margin Compression Weighs on Profitability

Despite stable gross margin, adjusted operating margin declined to 3.6% from 6.4% a year earlier, a drop of 280 basis points driven by higher operating costs and strategic investments. Management framed this as a deliberate trade-off to support long-term growth initiatives, though it acknowledged that investors will be watching closely for improvement over coming quarters.

Higher Selling Costs from Compensation Enhancements

Consolidated selling expense climbed to 34.3% of revenue, up from 32.5% a year ago, while core selling expense rose to about 40.5% from 38.7%. The increase was attributed largely to compensation plan enhancements designed to reward sales leader productivity, which management believes will support future top-line growth even as it keeps core selling expense near the 40% level.

G&A Mix Shifts Amid Cost Controls

Adjusted general and administrative expense declined by $9 million year over year in absolute dollars, reflecting ongoing cost-management efforts. However, G&A as a share of revenue still rose to 29.9% from 28.9%, driven by investments in technology and emerging market builds that are intended to underpin the next phase of expansion.

Prysm iO Transition Costs and Sales Model Shift

The rollout of Prysm iO is changing the sales model from demo-focused selling to more consultative wellness engagements, and this shift carries near-term friction. Training, new CRM tools, and behavior change among leaders are creating short-term switching costs that management expects will pressure productivity and margins before the model reaches full efficiency.

Macro and Segment Headwinds Persist

Executives flagged ongoing macro and geopolitical challenges, including tariffs, supply chain pressures, and rising fuel costs that are feeding into consumer price inflation as high as 16%–30% for some goods. Several segments remain under pressure in this environment, and management reiterated that India will remain a learning-focused, low-revenue market through 2026 as the company prioritizes setup over immediate sales.

Guidance Signals Sequential Improvement

Nu Skin reiterated its full-year outlook and issued second-quarter guidance calling for revenue between $330 million and $360 million and EPS of $0.15 to $0.25, assuming relatively neutral currency effects. The targets imply sequential improvement from Q1’s $320.6 million in revenue and $0.14 adjusted EPS, with management emphasizing continued investment in Prysm iO and emerging markets and promising more detailed updates after Q2.

Nu Skin’s earnings call presented a picture of a company in active transition, maintaining its revenue guidance while absorbing higher selling and operating costs to fund new platforms and markets. For investors, the key narrative is whether the early momentum in Prysm iO, nutrition, and regional growth can translate into sustained revenue gains and a gradual rebuilding of margins as 2024 progresses.